Merck (MSD) Clinical Trial Pipeline — 226 Active Studies

Merck (MSD) pipeline at a glance (March 2026)

About the Merck (MSD) clinical program

Merck (known as MSD outside the US) operates the world's most commercially successful immuno-oncology franchise, built around Keytruda (pembrolizumab), the anti-PD-1 checkpoint inhibitor. Keytruda has over 1,600 clinical trials registered globally — more than any single drug in history. In addition to Keytruda combinations, Merck is advancing next-generation IO programs including LAG-3, TIGIT, and tumor-infiltrating lymphocyte (TIL) therapies. In oncology beyond IO, Welireg (belzutifan) for HIF-2α-driven cancers (VHL disease, RCC) represents a new mechanism. Their infectious disease pipeline includes RSV vaccines, HIV treatments, and next-generation HPV-related programs.

Key therapeutic areas

• Immuno-oncology (PD-1 combinations)
• Next-generation IO (LAG-3, TIGIT, TIL)
• Solid tumors across all major indications
• Infectious disease / vaccines
• Rare metabolic disease (VHL, HIF-2α)

Key pipeline programs

• Keytruda (pembrolizumab) — PD-1 checkpoint, pan-tumor
• Welireg (belzutifan) — HIF-2α, RCC/VHL disease
• MK-2870 (sacituzumab tirumotecan) — TROP2 ADC
• Ladiratuzumab vedotin — LIV-1 ADC (breast/urothelial)
• MK-1308 (quavonlimab) — CTLA-4
• Islatravir — HIV NRTTI

Top Merck (MSD) trial indications

Condition / Indication	Trials
["Healthy"]	24
["Non-small Cell Lung Cancer"]	8
["Renal Cell Carcinoma"]	5
["Malignant Neoplasm"]	5
["Bladder Cancer"]	4
["Carcinoma, Non-Small-Cell Lung"]	4
["Non-small Cell Lung Cancer (NSCLC)"]	3
["Pneumococcal Infection"]	3

Why monitor Merck (MSD)'s clinical trial activity

Merck registers more new trials per month than any other industry sponsor. The Keytruda combination engine alone accounts for dozens of new trial registrations annually across tumor types. Competitive intelligence professionals covering any solid tumor must monitor Merck's pipeline.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Merck (MSD)'s registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks Merck (MSD) trials

• Sponsor normalization: Merck (MSD) may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

How many Keytruda (pembrolizumab) trials does Merck currently have active?

Keytruda is the most-trialed drug in history, with Merck-sponsored studies spanning virtually every solid tumor type. DataLookout lets you filter specifically for Merck-sponsored Keytruda combination trials in your indication of interest, rather than sifting through the full Keytruda universe.

How many Merck trials are currently recruiting?

Based on current ClinicalTrials.gov data, 113 Merck/MSD-sponsored trials are actively recruiting patients. This covers oncology, vaccines, and infectious disease programs.

Does DataLookout distinguish between Merck US and MSD (ex-US) trials?

DataLookout normalizes 'Merck Sharp & Dohme LLC', 'MSD', and related entities to a single canonical Merck entry, so you see the full global pipeline in one watchlist.